QUEST DIAGNOSTICS INC

NYSE: DGX·Secaucus, New Jersey·

Price
$262.21
Base IV
$206.92

Valuation snapshot

Above base case

At $262.21, the price sits between our base case ($206.92) and bull case ($338.71).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$206.92
79% of the price · range $99.12–$338.71
Price vs base case
27% above
$262.21 against $206.92
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $99.12 to bull $338.71. Values per share.

Price against each value

Bear case
$99.12
Price 165% above
No growth
…
—
Base case
$206.92
Price 27% above
Researched bygpt-6-sol
Valuation Oct 28, 2026 · Price as of Nov 16, 2026How we got here

What does Quest Diagnostics do?

Quest Diagnostics provides laboratory testing and diagnostic insights to physicians, hospitals, and patients to help identify and treat diseases and manage healthcare.

It brought in $11.8B of sales in the 12 months to Sep 2026.

Led by James E. Davis, Chairman, Chief Executive Officer and President since 2022. Quest Diagnostics - Management Team

Laboratory analyzers used for diagnostic testing.Bobjgalindo, CC BY-SA 4.0, via Wikimedia Commons
Industry
Healthcare
Based in
Secaucus, New Jersey
Trades on
NYSE as DGX

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 10¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 67¢ of every dollar.

  • Making what it sells67¢
  • Sales, marketing and admin17¢
  • Everything else it takes to operate1¢
  • Interest and other costs2¢
  • Tax3¢
  • Left as profit10¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Quest Diagnostics, and for what?

Quest Diagnostics runs laboratories and patient service centers that test blood, tissue and other samples. It earns most of its revenue by providing test results and related services to healthcare providers, patients, insurers and other organizations.

Its customers include physicians, hospitals, patients and consumers, health plans, government agencies, employers, pharmaceutical companies and insurers.

  • Diagnostic Information Services

    Laboratory and pathology testing, diagnostic insights and related services.

    Laboratory analyzers used for diagnostic testing.Bobjgalindo, CC BY-SA 4.0, via Wikimedia Commons
  • Diagnostic Solutions

    Risk assessment services for insurers and information technology solutions for healthcare organizations and clinicians.

  • Hospital reference testing

    11%

    Testing that hospitals send to Quest when they do not perform it in their own laboratories; Quest reported about $1.2 billion of this revenue in 2025.

  • Collaborative Lab Solutions

    7%

    Hospital lab support, including lab management, test menu and purchasing support, and data solutions; Quest reported about $800 million in revenue and management fees in 2025.

  • Advanced Diagnostics

    9%

    Specialized tests in areas including cancer, heart and metabolic health, brain health, autoimmune conditions, women's health and genetics generated more than $1 billion in 2025 revenue.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Clifton laboratory — Clifton, United States. This highly automated laboratory serves seven Northeastern states and has capacity for more than 300,000 tests per day.
  • Nichols Institute — San Juan Capistrano, United States. The institute performs complex specialty testing, including next-generation sequencing, and supports Quest’s diagnostic research and development.
  • Marlborough laboratory — Marlborough, United States. This major New England testing facility also houses a diagnostic research center focused on advanced technologies and specialized testing.
  • LifeLabs International Reference Laboratory — Toronto, Canada. This LifeLabs reference laboratory is a principal testing site in Quest’s Canadian diagnostic network.
  • Nichols Institute Chantilly — Chantilly, United States. This esoteric reference laboratory performs a broad range of specialized tests, including genetic and oncology testing.
See them on the globe

Quest Diagnostics 2025 Form 10-K, Item 1: Business

How is the business doing?

Sales grew from $9.4B in 2020 to $11B in 2025, about 3% a year.

Running the business leaves about 15¢ of each sales dollar as operating profit, down from 21¢ in 2020.

After paying for its upkeep and new investment, it had $1.4B of cash to spare in the 12 months to Sep 2026.

Sales$11B
20162025
Operating margin14%
20162025
Free cash flow$1.4B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company says its purpose is to work together to help create a healthier world, one life at a time.

“Working together to create a healthier world, one life at a time.”

About us | Quest Diagnostics

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

2026 revenue, Full year 2026
$12.065 billion to $12.105 billion
Quest Diagnostics Q3 2026 earnings call transcript
2026 adjusted diluted earnings per share, Full year 2026
$11.25 to $11.35
Quest Diagnostics Q3 2026 earnings call transcript
Consumer health growth, Full year 2026
More than 30%
Quest Diagnostics Q3 2026 earnings call transcript
Invigorate cost savings and productivity improvements, Annual
About 3% annually
Quest Diagnostics 2025 Form 10-K, Item 1: Business
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 10%.

Its operating margin is wider than a year ago: 15¢ per sales dollar, against 14¢.

Since Oct 2026 the share price has risen 4%, from $252.92 to $262.21.

Bull $338.71Base $206.92Bear $99.12Oct 30Nov 16 · $262.21
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Coming up

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Reimbursement and payment pressure

    Government programs and insurers can lower payment rates, limit coverage or require more approvals. Quest says Medicare rate changes under PAMA could reduce revenue, and it estimated an impact of about 1% of company revenue in 2027.

    From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  2. Competition and changing testing methods

    The company competes with commercial and hospital laboratories, physician offices and newer providers. Testing done at home or inside hospitals could reduce demand for Quest's services.

    From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  3. Failure to bring new tests to market

    If Quest cannot develop, license or successfully launch new tests and technologies, its services may become less competitive and testing volume or revenue could suffer.

    From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  4. Quality and testing errors

    Errors in testing or service could affect patient care, lead to legal claims and damage the company's reputation.

    From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  5. Privacy, cybersecurity and technology

    Quest handles sensitive patient information and relies on technology for testing, billing and service. A cyberattack, data breach or major system failure could disrupt operations, expose information and lead to legal or reputational harm.

    From the company's own filingsWould hit how much it has to reinvestQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  6. Debt and operating costs

    Quest had about $5.7 billion of debt at the end of 2025. Higher borrowing or labor and supply costs could reduce financial flexibility and put pressure on profitability.

    From the company's own filingsWould hit how much of each sale it keepsQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors

  7. Revenue per requisition fell 4.2% in the latest quarter even as requisition volume rose 14.5%.

    From our researchWould hit how fast sales growQuest Q3 2026 results

Is it a good business?

From 2016 to 2025 it earned between 8% and 19% on the capital invested in it, a median of 10%. Its cost of capital in the latest valuation is 7.3%; returns were above it in every one of the 10 years.

From 2016 to 2025 it earned between 13% and 31% on its shareholders' equity, a median of 15%.

Over 10 years its operating margin ranged from 14¢ to 22¢ per sales dollar, a median of 15¢. Gross margin ran from 33¢ to 39¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital9%
20162025

Cost of capital 7.3%

Return on equity14%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 23%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $4.8B more than it holds in cash, about 2.8 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $262.21. Our put its value between $99.12 and $338.71, with $206.92 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $99.12

Despite strong recent test growth, this case assumes lower payment per order and rising costs slow Quest's sales and reduce what it keeps from them.

Base case, $206.92

After a year of strong test growth, this case assumes Quest keeps adding orders at a slower pace while holding on to roughly its recent level of profit from sales.

Bull case, $338.71

Building on recent growth in test orders, this case assumes Quest keeps expanding quickly and earns more from its larger testing network.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 27%

For Quest Diagnostics to be worth today's $262.21, sales would need to grow about 10.6% a year. We assume 5.8%. Over the last 5 years, sales grew 1.4% a year.

−2.5%0%+2.5%+5%+7.5%+10%+12.5%Past 5 yrs 1.4%We assume 5.8%Price needs 10.6%

Or, if sales grow 5.8% as we assume, the price works with a profit margin of 18.3% (we assume 15.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 10.6% a year?

Try your own numbers

We're moderately sure of this range: it scores 59 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $206.92 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average5.8%
  • Operating margin15.0%
  • Long-term growth rate2.2%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$206.92 -21.1%

Build